APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Monoclonal Antibodies Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Therapeutic Monoclonal Antibodies Drug Market Analysis and Forecast 2026-2032

24 December 2025214 pages

Choose your research edition.

Industry ResearchTherapeutic Monoclonal Antibodies Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Monoclonal Antibodies Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Therapeutic Monoclonal Antibodies Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Monoclonal Antibodies Drug Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Monoclonal Antibodies Drug Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Therapeutic Monoclonal Antibodies Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

Therapeutic Monoclonal Antibodies Drug's global sales reached XX (Tons) with a value of US$ XX Million, marking an change of XX% compared to the previous year. This performance has positioned AbbVie as the global sales leader, a title it has maintained for several consecutive years. Notably, AbbVie's performance in primary markets is also remarkable. In the Chinese market, sales were XX (Tons), a change of XX% from the previous year. In Europe, sales were XX (Tons), showing a year-on-year of XX%. In the US, sales were XX (Tons), a year-on-year change of XX%.

The major global manufacturers in the Therapeutic Monoclonal Antibodies Drug market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck & Co, Novartis and Roche, etc. In 2025, the top three vendors accounted for approximately % of the revenue.

Read the full market overview

In terms of production side, this report researches the Therapeutic Monoclonal Antibodies Drug production, growth rate, market share by manufacturers and by region (region level and country level), from 2021 to 2026, and forecast to 2032.

In terms of consumption side, this report focuses on the sales of Therapeutic Monoclonal Antibodies Drug by region (region level and country level), by Company, by Type and by Application. from 2021 to 2026 and forecast to 2032.

This report presents an overview of global market for Therapeutic Monoclonal Antibodies Drug, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Therapeutic Monoclonal Antibodies Drug, also provides the consumption of main regions and countries. Of the upcoming market potential for Therapeutic Monoclonal Antibodies Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Therapeutic Monoclonal Antibodies Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Therapeutic Monoclonal Antibodies Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Therapeutic Monoclonal Antibodies Drug sales, projected growth trends, production technology, application and end-user industry.

Therapeutic Monoclonal Antibodies Drug Segment by Company

AbbVie

Amgen

AstraZeneca

Bristol-Myers Squibb

Gilead Sciences

Johnson & Johnson

Merck & Co

Novartis

Roche

Innovent

Merck KGaA

Takeda

Seagen

Regeneron

Pfizer

Ono Pharmaceutical

Eli Lilly

Hengrui Medicine

Therapeutic Monoclonal Antibodies Drug Segment by Type

Chimeric Antibodies

Humanized Antibodies

Mouse-derived Antibodies

Therapeutic Monoclonal Antibodies Drug Segment by Application

Immune Diseases

Cancer

Other

Therapeutic Monoclonal Antibodies Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Monoclonal Antibodies Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Monoclonal Antibodies Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Monoclonal Antibodies Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Therapeutic Monoclonal Antibodies Drug production/output of global and key producers (regions/countries). It provides a quantitative analysis of the production, and development potential of each producer in the next six years.

Chapter 4: Sales (consumption), revenue of Therapeutic Monoclonal Antibodies Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 5: Detailed analysis of Therapeutic Monoclonal Antibodies Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Therapeutic Monoclonal Antibodies Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 9: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 10: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 11: China by type, by application, sales, and revenue for each segment.

Chapter 12: Asia (Excluding China) by type, by application and by region, sales, and revenue for each segment.

Chapter 13: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 14: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 15: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chimeric Antibodies Major Manufacturers Table 3. Humanized Antibodies Major Manufacturers Table 4. Mouse-derived Antibodies Major Manufacturers Table 5. Global Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Immune Diseases Major Manufacturers Table 7. Cancer Major Manufacturers Table 8. Other Major Manufacturers Table 9. Therapeutic Monoclonal Antibodies Drug Industry Trends Table 10. Therapeutic Monoclonal Antibodies Drug Industry Drivers Table 11. Therapeutic Monoclonal Antibodies Drug Industry Opportunities and Challenges Table 12. Therapeutic Monoclonal Antibodies Drug Industry Restraints Table 13. Global Therapeutic Monoclonal Antibodies Drug Production Growth Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Tons) Table 14. Global Therapeutic Monoclonal Antibodies Drug Production by Region (2021-2026) & (Tons) Table 15. Global Therapeutic Monoclonal Antibodies Drug Production by Region (2027-2032) & (Tons) Table 16. Global Therapeutic Monoclonal Antibodies Drug Production Market Share by Region (2021-2026) Table 17. Global Therapeutic Monoclonal Antibodies Drug Production Market Share by Region (2027-2032) Table 18. Global Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Therapeutic Monoclonal Antibodies Drug Revenue by Region (2021-2026) & (US$ Million) Table 20. Global Therapeutic Monoclonal Antibodies Drug Revenue by Region (2027-2032) & (US$ Million) Table 21. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Region (2021-2026) Table 22. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Region (2027-2032) Table 23. Global Therapeutic Monoclonal Antibodies Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Tons) Table 24. Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2021-2026) & (Tons) Table 25. Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2027-2032) & (Tons) Table 26. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2021-2026) Table 27. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2027-2032) Table 28. Global Therapeutic Monoclonal Antibodies Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Manufacturers (2021-2026) Table 30. Global Therapeutic Monoclonal Antibodies Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 31. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Manufacturers (2021-2026) Table 32. Global Therapeutic Monoclonal Antibodies Drug Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 33. Global Therapeutic Monoclonal Antibodies Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 34. Global Therapeutic Monoclonal Antibodies Drug Key Manufacturers Manufacturing Sites & Headquarters Table 35. Global Therapeutic Monoclonal Antibodies Drug Manufacturers, Product Type & Application Table 36. Global Therapeutic Monoclonal Antibodies Drug Manufacturers Commercialization Time Table 37. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 38. Global Therapeutic Monoclonal Antibodies Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 39. Global Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Therapeutic Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Type (2021-2026) Table 42. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Type (2027-2032) Table 43. Global Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 44. Global Therapeutic Monoclonal Antibodies Drug Sales by Type (2027-2032) & (Tons) Table 45. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2021-2026) Table 46. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2027-2032) Table 47. Global Therapeutic Monoclonal Antibodies Drug Price by Type (2021-2026) & (US$/Ton) Table 48. Global Therapeutic Monoclonal Antibodies Drug Price by Type (2027-2032) & (US$/Ton) Table 49. Global Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Therapeutic Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Application (2021-2026) Table 52. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Application (2027-2032) Table 53. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 54. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2027-2032) & (Tons) Table 55. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2021-2026) Table 56. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2027-2032) Table 57. Global Therapeutic Monoclonal Antibodies Drug Price by Application (2021-2026) & (US$/Ton) Table 58. Global Therapeutic Monoclonal Antibodies Drug Price by Application (2027-2032) & (US$/Ton) Table 59. AbbVie Company Information Table 60. AbbVie Business Overview Table 61. AbbVie Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 62. AbbVie Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 63. AbbVie Recent Development Table 64. Amgen Company Information Table 65. Amgen Business Overview Table 66. Amgen Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 67. Amgen Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 68. Amgen Recent Development Table 69. AstraZeneca Company Information Table 70. AstraZeneca Business Overview Table 71. AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 72. AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 73. AstraZeneca Recent Development Table 74. Bristol-Myers Squibb Company Information Table 75. Bristol-Myers Squibb Business Overview Table 76. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 77. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 78. Bristol-Myers Squibb Recent Development Table 79. Gilead Sciences Company Information Table 80. Gilead Sciences Business Overview Table 81. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 82. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 83. Gilead Sciences Recent Development Table 84. Johnson & Johnson Company Information Table 85. Johnson & Johnson Business Overview Table 86. Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 87. Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 88. Johnson & Johnson Recent Development Table 89. Merck & Co Company Information Table 90. Merck & Co Business Overview Table 91. Merck & Co Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 92. Merck & Co Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 93. Merck & Co Recent Development Table 94. Novartis Company Information Table 95. Novartis Business Overview Table 96. Novartis Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 97. Novartis Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 98. Novartis Recent Development Table 99. Roche Company Information Table 100. Roche Business Overview Table 101. Roche Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 102. Roche Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 103. Roche Recent Development Table 104. Innovent Company Information Table 105. Innovent Business Overview Table 106. Innovent Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 107. Innovent Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 108. Innovent Recent Development Table 109. Merck KGaA Company Information Table 110. Merck KGaA Business Overview Table 111. Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 112. Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 113. Merck KGaA Recent Development Table 114. Takeda Company Information Table 115. Takeda Business Overview Table 116. Takeda Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 117. Takeda Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 118. Takeda Recent Development Table 119. Seagen Company Information Table 120. Seagen Business Overview Table 121. Seagen Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 122. Seagen Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 123. Seagen Recent Development Table 124. Regeneron Company Information Table 125. Regeneron Business Overview Table 126. Regeneron Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 127. Regeneron Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 128. Regeneron Recent Development Table 129. Pfizer Company Information Table 130. Pfizer Business Overview Table 131. Pfizer Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 132. Pfizer Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 133. Pfizer Recent Development Table 134. Ono Pharmaceutical Company Information Table 135. Ono Pharmaceutical Business Overview Table 136. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 137. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 138. Ono Pharmaceutical Recent Development Table 139. Eli Lilly Company Information Table 140. Eli Lilly Business Overview Table 141. Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 142. Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 143. Eli Lilly Recent Development Table 144. Hengrui Medicine Company Information Table 145. Hengrui Medicine Business Overview Table 146. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 147. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Portfolio Table 148. Hengrui Medicine Recent Development Table 149. North America Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 150. North America Therapeutic Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 151. North America Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 152. North America Therapeutic Monoclonal Antibodies Drug Sales by Type (2027-2032) & (Tons) Table 153. North America Therapeutic Monoclonal Antibodies Drug Sales Price by Type (2021-2026) & (US$/Ton) Table 154. North America Therapeutic Monoclonal Antibodies Drug Sales Price by Type (2027-2032) & (US$/Ton) Table 155. North America Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 156. North America Therapeutic Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 157. North America Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 158. North America Therapeutic Monoclonal Antibodies Drug Sales by Application (2027-2032) & (Tons) Table 159. North America Therapeutic Monoclonal Antibodies Drug Sales Price by Application (2021-2026) & (US$/Ton) Table 160. North America Therapeutic Monoclonal Antibodies Drug Sales Price by Application (2027-2032) & (US$/Ton) Table 161. North America Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. North America Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. North America Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. North America Therapeutic Monoclonal Antibodies Drug Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 165. North America Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons) Table 166. North America Therapeutic Monoclonal Antibodies Drug Sales by Country (2027-2032) & (Tons) Table 167. North America Therapeutic Monoclonal Antibodies Drug Sales Price by Country (2021-2026) & (US$/Ton) Table 168. North America Therapeutic Monoclonal Antibodies Drug Sales Price by Country (2027-2032) & (US$/Ton) Table 169. United States Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 170. Canada Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 171. Mexico Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 172. Europe Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 173. Europe Therapeutic Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 174. Europe Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 175. Europe Therapeutic Monoclonal Antibodies Drug Sales by Type (2027-2032) & (Tons) Table 176. Europe Therapeutic Monoclonal Antibodies Drug Sales Price by Type (2021-2026) & (US$/Ton) Table 177. Europe Therapeutic Monoclonal Antibodies Drug Sales Price by Type (2027-2032) & (US$/Ton) Table 178. Europe Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 179. Europe Therapeutic Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 180. Europe Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 181. Europe Therapeutic Monoclonal Antibodies Drug Sales by Application (2027-2032) & (Tons) Table 182. Europe Therapeutic Monoclonal Antibodies Drug Sales Price by Application (2021-2026) & (US$/Ton) Table 183. Europe Therapeutic Monoclonal Antibodies Drug Sales Price by Application (2027-2032) & (US$/Ton) Table 184. Europe Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. Europe Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. Europe Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. Europe Therapeutic Monoclonal Antibodies Drug Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 188. Europe Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons) Table 189. Europe Therapeutic Monoclonal Antibodies Drug Sales by Country (2027-2032) & (Tons) Table 190. Europe Therapeutic Monoclonal Antibodies Drug Sales Price by Country (2021-2026) & (US$/Ton) Table 191. Europe Therapeutic Monoclonal Antibodies Drug Sales Price by Country (2027-2032) & (US$/Ton) Table 192. Germany Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 193. France Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 194. U.K. Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 195. Italy Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 196. Russia Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 197. Spain Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 198. Netherlands Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 199. Switzerland Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 200. Sweden Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 201. Poland Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 202. China Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 203. China Therapeutic Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 204. China Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 205. China Therapeutic Monoclonal Antibodies Drug Sales by Type (2027-2032) & (Tons) Table 206. China Therapeutic Monoclonal Antibodies Drug Sales Price by Type (2021-2026) & (US$/Ton) Table 207. China Therapeutic Monoclonal Antibodies Drug Sales Price by Type (2027-2032) & (US$/Ton) Table 208. China Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 209. China Therapeutic Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 210. China Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 211. China Therapeutic Monoclonal Antibodies Drug Sales by Application (2027-2032) & (Tons) Table 212. China Therapeutic Monoclonal Antibodies Drug Sales Price by Application (2021-2026) & (US$/Ton) Table 213. China Therapeutic Monoclonal Antibodies Drug Sales Price by Application (2027-2032) & (US$/Ton) Table 214. Asia Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 215. Asia Therapeutic Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 216. Asia Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 217. Asia Therapeutic Monoclonal Antibodies Drug Sales by Type (2027-2032) & (Tons) Table 218. Asia Therapeutic Monoclonal Antibodies Drug Sales Price by Type (2021-2026) & (US$/Ton) Table 219. Asia Therapeutic Monoclonal Antibodies Drug Sales Price by Type (2027-2032) & (US$/Ton) Table 220. Asia Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 221. Asia Therapeutic Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 222. Asia Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 223. Asia Therapeutic Monoclonal Antibodies Drug Sales by Application (2027-2032) & (Tons) Table 224. Asia Therapeutic Monoclonal Antibodies Drug Sales Price by Application (2021-2026) & (US$/Ton) Table 225. Asia Therapeutic Monoclonal Antibodies Drug Sales Price by Application (2027-2032) & (US$/Ton) Table 226. Asia Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 227. Asia Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 228. Asia Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 229. Asia Therapeutic Monoclonal Antibodies Drug Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 230. Asia Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons) Table 231. Asia Therapeutic Monoclonal Antibodies Drug Sales by Country (2027-2032) & (Tons) Table 232. Asia Therapeutic Monoclonal Antibodies Drug Sales Price by Country (2021-2026) & (US$/Ton) Table 233. Asia Therapeutic Monoclonal Antibodies Drug Sales Price by Country (2027-2032) & (US$/Ton) Table 234. Japan Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 235. South Korea Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 236. India Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 237. Australia Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 238. Taiwan Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 239. Southeast Asia Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 240. SAMEA Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (US$ Million) Table 241. SAMEA Therapeutic Monoclonal Antibodies Drug Revenue by Type (2027-2032) & (US$ Million) Table 242. SAMEA Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons) Table 243. SAMEA Therapeutic Monoclonal Antibodies Drug Sales by Type (2027-2032) & (Tons) Table 244. SAMEA Therapeutic Monoclonal Antibodies Drug Sales Price by Type (2021-2026) & (US$/Ton) Table 245. SAMEA Therapeutic Monoclonal Antibodies Drug Sales Price by Type (2027-2032) & (US$/Ton) Table 246. SAMEA Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (US$ Million) Table 247. SAMEA Therapeutic Monoclonal Antibodies Drug Revenue by Application (2027-2032) & (US$ Million) Table 248. SAMEA Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons) Table 249. SAMEA Therapeutic Monoclonal Antibodies Drug Sales by Application (2027-2032) & (Tons) Table 250. SAMEA Therapeutic Monoclonal Antibodies Drug Sales Price by Application (2021-2026) & (US$/Ton) Table 251. SAMEA Therapeutic Monoclonal Antibodies Drug Sales Price by Application (2027-2032) & (US$/Ton) Table 252. SAMEA Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 253. SAMEA Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 254. SAMEA Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 255. SAMEA Therapeutic Monoclonal Antibodies Drug Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 256. SAMEA Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons) Table 257. SAMEA Therapeutic Monoclonal Antibodies Drug Sales by Country (2027-2032) & (Tons) Table 258. SAMEA Therapeutic Monoclonal Antibodies Drug Sales Price by Country (2021-2026) & (US$/Ton) Table 259. SAMEA Therapeutic Monoclonal Antibodies Drug Sales Price by Country (2027-2032) & (US$/Ton) Table 260. Brazil Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 261. Argentina Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 262. Chile Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 263. Colombia Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 264. Peru Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 265. Saudi Arabia Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 266. Israel Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 267. UAE Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 268. Turkey Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 269. Iran Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 270. Egypt Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Table 271. Key Raw Materials Table 272. Raw Materials Key Suppliers Table 273. Therapeutic Monoclonal Antibodies Drug Distributors List Table 274. Therapeutic Monoclonal Antibodies Drug Customers List Table 275. Research Programs/Design for This Report Table 276. Authors List of This Report Table 277. Secondary Sources Table 278. Primary Sources List of Figures Figure 1. Therapeutic Monoclonal Antibodies Drug Product Image Figure 2. Global Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Monoclonal Antibodies Drug Market Size Share 2021 VS 2025 VS 2032 Figure . Chimeric Antibodies Image Figure 1. Humanized Antibodies Image Figure 2. Mouse-derived Antibodies Image Figure 3. Global Therapeutic Monoclonal Antibodies Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Therapeutic Monoclonal Antibodies Drug Market Size Share 2021 VS 2025 VS 2032 Figure 5. Immune Diseases Image Figure 6. Cancer Image Figure 7. Other Image Figure 8. Global Therapeutic Monoclonal Antibodies Drug Capacity, Capacity Utilization (2021-2032) & (Tons) Figure 9. Global Therapeutic Monoclonal Antibodies Drug Production by Region: 2021 VS 2025 VS 2032 (Tons) Figure 10. Global Therapeutic Monoclonal Antibodies Drug Production Market Share by Region: 2025 Versus 2032 Figure 11. Global Therapeutic Monoclonal Antibodies Drug Production Market Share by Region (2021-2032) Figure 12. North America Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2021-2032) & (Tons) Figure 13. Europe Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2021-2032) & (Tons) Figure 14. China Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2021-2032) & (Tons) Figure 15. Japan Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2021-2032) & (Tons) Figure 16. Global Therapeutic Monoclonal Antibodies Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Therapeutic Monoclonal Antibodies Drug Revenue (2021-2032) & (US$ Million) Figure 18. Global Therapeutic Monoclonal Antibodies Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Region (2021-2032) Figure 21. Global Therapeutic Monoclonal Antibodies Drug Sales (2021-2032) & (Tons) Figure 22. Global Therapeutic Monoclonal Antibodies Drug Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 23. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2021-2032) Figure 24. North America Therapeutic Monoclonal Antibodies Drug Sales YoY (2021-2032) & (Tons) Figure 25. Europe Therapeutic Monoclonal Antibodies Drug Sales YoY (2021-2032) & (Tons) Figure 26. China Therapeutic Monoclonal Antibodies Drug Sales YoY (2021-2032) & (Tons) Figure 27. Asia (Excluding China) Therapeutic Monoclonal Antibodies Drug Sales YoY (2021-2032) & (Tons) Figure 28. South America, Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales YoY (2021-2032) & (Tons) Figure 29. Global Therapeutic Monoclonal Antibodies Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Therapeutic Monoclonal Antibodies Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Type (2021-2032) Figure 33. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2021-2032) Figure 34. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Application (2021-2032) Figure 35. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2021-2032) Figure 36. North America Therapeutic Monoclonal Antibodies Drug Revenue Share by Type (2021-2032) Figure 37. North America Therapeutic Monoclonal Antibodies Drug Sales Share by Type (2021-2032) Figure 38. North America Therapeutic Monoclonal Antibodies Drug Revenue Share by Application (2021-2032) Figure 39. North America Therapeutic Monoclonal Antibodies Drug Sales Share by Application (2021-2032) Figure 40. North America Therapeutic Monoclonal Antibodies Drug Revenue Share by Country (2021-2032) Figure 41. North America Therapeutic Monoclonal Antibodies Drug Sales Share by Country (2021-2032) Figure 42. Europe Therapeutic Monoclonal Antibodies Drug Revenue Share by Type (2021-2032) Figure 43. Europe Therapeutic Monoclonal Antibodies Drug Sales Share by Type (2021-2032) Figure 44. Europe Therapeutic Monoclonal Antibodies Drug Revenue Share by Application (2021-2032) Figure 45. Europe Therapeutic Monoclonal Antibodies Drug Sales Share by Application (2021-2032) Figure 46. Europe Therapeutic Monoclonal Antibodies Drug Revenue Share by Country (2021-2032) Figure 47. Europe Therapeutic Monoclonal Antibodies Drug Sales Share by Country (2021-2032) Figure 48. China Therapeutic Monoclonal Antibodies Drug Revenue Share by Type (2021-2032) Figure 49. China Therapeutic Monoclonal Antibodies Drug Sales Share by Type (2021-2032) Figure 50. China Therapeutic Monoclonal Antibodies Drug Revenue Share by Application (2021-2032) Figure 51. China Therapeutic Monoclonal Antibodies Drug Sales Share by Application (2021-2032) Figure 52. Asia Therapeutic Monoclonal Antibodies Drug Revenue Share by Type (2021-2032) Figure 53. Asia Therapeutic Monoclonal Antibodies Drug Sales Share by Type (2021-2032) Figure 54. Asia Therapeutic Monoclonal Antibodies Drug Revenue Share by Application (2021-2032) Figure 55. Asia Therapeutic Monoclonal Antibodies Drug Sales Share by Application (2021-2032) Figure 56. Asia Therapeutic Monoclonal Antibodies Drug Revenue Share by Country (2021-2032) Figure 57. Asia Therapeutic Monoclonal Antibodies Drug Sales Share by Country (2021-2032) Figure 58. SAMEA Therapeutic Monoclonal Antibodies Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Therapeutic Monoclonal Antibodies Drug Sales Share by Type (2021-2032) Figure 60. SAMEA Therapeutic Monoclonal Antibodies Drug Revenue Share by Application (2021-2032) Figure 61. SAMEA Therapeutic Monoclonal Antibodies Drug Sales Share by Application (2021-2032) Figure 62. SAMEA Therapeutic Monoclonal Antibodies Drug Revenue Share by Country (2021-2032) Figure 63. SAMEA Therapeutic Monoclonal Antibodies Drug Sales Share by Country (2021-2032) Figure 64. Therapeutic Monoclonal Antibodies Drug Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Therapeutic Monoclonal Antibodies Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Chimeric Antibodies
  • Humanized Antibodies
  • Mouse-derived Antibodies
Applications
  • Immune Diseases
  • Cancer
  • Other
Companies covered
  • AbbVie
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Johnson & Johnson
  • Merck & Co
  • Novartis
  • Roche
  • Innovent
  • Merck KGaA
  • Takeda
  • Seagen
  • Regeneron
  • Pfizer
  • Ono Pharmaceutical
  • Eli Lilly
  • Hengrui Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Therapeutic Monoclonal Antibodies Drug Market by Type
  3. 1.2.1 Global Therapeutic Monoclonal Antibodies Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chimeric Antibodies
  5. 1.2.3 Humanized Antibodies
  6. 1.2.4 Mouse-derived Antibodies
  7. 1.3 Therapeutic Monoclonal Antibodies Drug Market by Application
  8. 1.3.1 Global Therapeutic Monoclonal Antibodies Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Immune Diseases
  10. 1.3.3 Cancer
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Therapeutic Monoclonal Antibodies Drug Market Dynamics
  1. 2.1 Therapeutic Monoclonal Antibodies Drug Industry Trends
  2. 2.2 Therapeutic Monoclonal Antibodies Drug Industry Drivers
  3. 2.3 Therapeutic Monoclonal Antibodies Drug Industry Opportunities and Challenges
  4. 2.4 Therapeutic Monoclonal Antibodies Drug Industry Restraints
3 Global Therapeutic Monoclonal Antibodies Drug Production Overview
  1. 3.1 Global Therapeutic Monoclonal Antibodies Drug Production Capacity (2021-2032)
  2. 3.2 Global Therapeutic Monoclonal Antibodies Drug Production by Region: 2021 VS 2025 VS 2032
  3. 3.3 Global Therapeutic Monoclonal Antibodies Drug Production by Region
  4. 3.3.1 Global Therapeutic Monoclonal Antibodies Drug Production by Region (2021-2026)
  5. 3.3.2 Global Therapeutic Monoclonal Antibodies Drug Production by Region (2027-2032)
  6. 3.3.3 Global Therapeutic Monoclonal Antibodies Drug Production Market Share by Region (2021-2032)
  7. 3.4 North America
  8. 3.5 Europe
  9. 3.6 China
  10. 3.7 Japan
4 Global Market Growth Prospects
  1. 4.1 Global Therapeutic Monoclonal Antibodies Drug Revenue Estimates and Forecasts (2021-2032)
  2. 4.2 Global Therapeutic Monoclonal Antibodies Drug Revenue by Region
  3. 4.2.1 Global Therapeutic Monoclonal Antibodies Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 4.2.2 Global Therapeutic Monoclonal Antibodies Drug Revenue by Region (2021-2026)
  5. 4.2.3 Global Therapeutic Monoclonal Antibodies Drug Revenue by Region (2027-2032)
  6. 4.2.4 Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Region (2021-2032)
  7. 4.3 Global Therapeutic Monoclonal Antibodies Drug Sales Estimates and Forecasts 2021-2032
  8. 4.4 Global Therapeutic Monoclonal Antibodies Drug Sales by Region
  9. 4.4.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 4.4.2 Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2021-2026)
  11. 4.4.3 Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2027-2032)
  12. 4.4.4 Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2021-2032)
  13. 4.5 North America
  14. 4.6 Europe
  15. 4.7 China
  16. 4.8 Asia (Excluding China)
  17. 4.9 South America, Middle East and Africa
5 Market Competitive Landscape by Manufacturers
  1. 5.1 Global Therapeutic Monoclonal Antibodies Drug Revenue by Manufacturers
  2. 5.1.1 Global Therapeutic Monoclonal Antibodies Drug Revenue by Manufacturers (2021-2026)
  3. 5.1.2 Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 5.1.3 Global Therapeutic Monoclonal Antibodies Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 5.2 Global Therapeutic Monoclonal Antibodies Drug Sales by Manufacturers
  6. 5.2.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Manufacturers (2021-2026)
  7. 5.2.2 Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Manufacturers (2021-2026)
  8. 5.2.3 Global Therapeutic Monoclonal Antibodies Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 5.3 Global Therapeutic Monoclonal Antibodies Drug Sales Price by Manufacturers (2021-2026)
  10. 5.4 Global Therapeutic Monoclonal Antibodies Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 5.5 Global Therapeutic Monoclonal Antibodies Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 5.6 Global Therapeutic Monoclonal Antibodies Drug Manufacturers, Product Type & Application
  13. 5.7 Global Therapeutic Monoclonal Antibodies Drug Manufacturers Commercialization Time
  14. 5.8 Market Competitive Analysis
  15. 5.8.1 Global Therapeutic Monoclonal Antibodies Drug Market CR5 and HHI
  16. 5.8.2 2025 Therapeutic Monoclonal Antibodies Drug Tier 1, Tier 2, and Tier 3
6 Therapeutic Monoclonal Antibodies Drug Market by Type
  1. 6.1 Global Therapeutic Monoclonal Antibodies Drug Revenue by Type
  2. 6.1.1 Global Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2032) & (US$ Million)
  3. 6.1.2 Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Type (2021-2032)
  4. 6.2 Global Therapeutic Monoclonal Antibodies Drug Sales by Type
  5. 6.2.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2032) & (Tons)
  6. 6.2.2 Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2021-2032)
  7. 6.3 Global Therapeutic Monoclonal Antibodies Drug Price by Type
7 Therapeutic Monoclonal Antibodies Drug Market by Application
  1. 7.1 Global Therapeutic Monoclonal Antibodies Drug Revenue by Application
  2. 7.1.1 Global Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2032) & (US$ Million)
  3. 7.1.2 Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Application (2021-2032)
  4. 7.2 Global Therapeutic Monoclonal Antibodies Drug Sales by Application
  5. 7.2.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2032) & (Tons)
  6. 7.2.2 Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2021-2032)
  7. 7.3 Global Therapeutic Monoclonal Antibodies Drug Price by Application
8 Company Profiles
  1. 8.1 AbbVie
  2. 8.1.1 AbbVie Company Information
  3. 8.1.2 AbbVie Business Overview
  4. 8.1.3 AbbVie Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Therapeutic Monoclonal Antibodies Drug Product Portfolio
  6. 8.1.5 AbbVie Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Therapeutic Monoclonal Antibodies Drug Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 AstraZeneca
  14. 8.3.1 AstraZeneca Company Information
  15. 8.3.2 AstraZeneca Business Overview
  16. 8.3.3 AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Portfolio
  18. 8.3.5 AstraZeneca Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Gilead Sciences
  26. 8.5.1 Gilead Sciences Company Information
  27. 8.5.2 Gilead Sciences Business Overview
  28. 8.5.3 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Portfolio
  30. 8.5.5 Gilead Sciences Recent Developments
  31. 8.6 Johnson & Johnson
  32. 8.6.1 Johnson & Johnson Company Information
  33. 8.6.2 Johnson & Johnson Business Overview
  34. 8.6.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 8.6.4 Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Product Portfolio
  36. 8.6.5 Johnson & Johnson Recent Developments
  37. 8.7 Merck & Co
  38. 8.7.1 Merck & Co Company Information
  39. 8.7.2 Merck & Co Business Overview
  40. 8.7.3 Merck & Co Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 8.7.4 Merck & Co Therapeutic Monoclonal Antibodies Drug Product Portfolio
  42. 8.7.5 Merck & Co Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Therapeutic Monoclonal Antibodies Drug Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 8.9.4 Roche Therapeutic Monoclonal Antibodies Drug Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Innovent
  56. 8.10.1 Innovent Company Information
  57. 8.10.2 Innovent Business Overview
  58. 8.10.3 Innovent Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 8.10.4 Innovent Therapeutic Monoclonal Antibodies Drug Product Portfolio
  60. 8.10.5 Innovent Recent Developments
  61. 8.11 Merck KGaA
  62. 8.11.1 Merck KGaA Company Information
  63. 8.11.2 Merck KGaA Business Overview
  64. 8.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 8.11.4 Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Portfolio
  66. 8.11.5 Merck KGaA Recent Developments
  67. 8.12 Takeda
  68. 8.12.1 Takeda Company Information
  69. 8.12.2 Takeda Business Overview
  70. 8.12.3 Takeda Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 8.12.4 Takeda Therapeutic Monoclonal Antibodies Drug Product Portfolio
  72. 8.12.5 Takeda Recent Developments
  73. 8.13 Seagen
  74. 8.13.1 Seagen Company Information
  75. 8.13.2 Seagen Business Overview
  76. 8.13.3 Seagen Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 8.13.4 Seagen Therapeutic Monoclonal Antibodies Drug Product Portfolio
  78. 8.13.5 Seagen Recent Developments
  79. 8.14 Regeneron
  80. 8.14.1 Regeneron Company Information
  81. 8.14.2 Regeneron Business Overview
  82. 8.14.3 Regeneron Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 8.14.4 Regeneron Therapeutic Monoclonal Antibodies Drug Product Portfolio
  84. 8.14.5 Regeneron Recent Developments
  85. 8.15 Pfizer
  86. 8.15.1 Pfizer Company Information
  87. 8.15.2 Pfizer Business Overview
  88. 8.15.3 Pfizer Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 8.15.4 Pfizer Therapeutic Monoclonal Antibodies Drug Product Portfolio
  90. 8.15.5 Pfizer Recent Developments
  91. 8.16 Ono Pharmaceutical
  92. 8.16.1 Ono Pharmaceutical Company Information
  93. 8.16.2 Ono Pharmaceutical Business Overview
  94. 8.16.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 8.16.4 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Portfolio
  96. 8.16.5 Ono Pharmaceutical Recent Developments
  97. 8.17 Eli Lilly
  98. 8.17.1 Eli Lilly Company Information
  99. 8.17.2 Eli Lilly Business Overview
  100. 8.17.3 Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 8.17.4 Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Portfolio
  102. 8.17.5 Eli Lilly Recent Developments
  103. 8.18 Hengrui Medicine
  104. 8.18.1 Hengrui Medicine Company Information
  105. 8.18.2 Hengrui Medicine Business Overview
  106. 8.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 8.18.4 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Portfolio
  108. 8.18.5 Hengrui Medicine Recent Developments
9 North America
  1. 9.1 North America Therapeutic Monoclonal Antibodies Drug Market Size by Type
  2. 9.1.1 North America Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 9.1.2 North America Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2032)
  4. 9.1.3 North America Therapeutic Monoclonal Antibodies Drug Price by Type (2021-2032)
  5. 9.2 North America Therapeutic Monoclonal Antibodies Drug Market Size by Application
  6. 9.2.1 North America Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  7. 9.2.2 North America Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2032)
  8. 9.2.3 North America Therapeutic Monoclonal Antibodies Drug Price by Application (2021-2032)
  9. 9.3 North America Therapeutic Monoclonal Antibodies Drug Market Size by Country
  10. 9.3.1 North America Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 North America Therapeutic Monoclonal Antibodies Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 North America Therapeutic Monoclonal Antibodies Drug Price by Country (2021-2032)
  13. 9.3.4 United States
  14. 9.3.5 Canada
  15. 9.3.6 Mexico
10 Europe
  1. 10.1 Europe Therapeutic Monoclonal Antibodies Drug Market Size by Type
  2. 10.1.1 Europe Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 10.1.2 Europe Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2032)
  4. 10.1.3 Europe Therapeutic Monoclonal Antibodies Drug Price by Type (2021-2032)
  5. 10.2 Europe Therapeutic Monoclonal Antibodies Drug Market Size by Application
  6. 10.2.1 Europe Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  7. 10.2.2 Europe Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2032)
  8. 10.2.3 Europe Therapeutic Monoclonal Antibodies Drug Price by Application (2021-2032)
  9. 10.3 Europe Therapeutic Monoclonal Antibodies Drug Market Size by Country
  10. 10.3.1 Europe Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 10.3.2 Europe Therapeutic Monoclonal Antibodies Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 10.3.3 Europe Therapeutic Monoclonal Antibodies Drug Price by Country (2021-2032)
  13. 10.3.4 Germany
  14. 10.3.5 France
  15. 10.3.6 U.K.
  16. 10.3.7 Italy
  17. 10.3.8 Russia
  18. 10.3.9 Spain
  19. 10.3.10 Netherlands
  20. 10.3.11 Switzerland
  21. 10.3.12 Sweden
11 China
  1. 11.1 China Therapeutic Monoclonal Antibodies Drug Market Size by Type
  2. 11.1.1 China Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 11.1.2 China Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2032)
  4. 11.1.3 China Therapeutic Monoclonal Antibodies Drug Price by Type (2021-2032)
  5. 11.2 China Therapeutic Monoclonal Antibodies Drug Market Size by Application
  6. 11.2.1 China Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  7. 11.2.2 China Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2032)
  8. 11.2.3 China Therapeutic Monoclonal Antibodies Drug Price by Application (2021-2032)
12 Asia (Excluding China)
  1. 12.1 Asia Therapeutic Monoclonal Antibodies Drug Market Size by Type
  2. 12.1.1 Asia Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 12.1.2 Asia Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2032)
  4. 12.1.3 Asia Therapeutic Monoclonal Antibodies Drug Price by Type (2021-2032)
  5. 12.2 Asia Therapeutic Monoclonal Antibodies Drug Market Size by Application
  6. 12.2.1 Asia Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  7. 12.2.2 Asia Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2032)
  8. 12.2.3 Asia Therapeutic Monoclonal Antibodies Drug Price by Application (2021-2032)
  9. 12.3 Asia Therapeutic Monoclonal Antibodies Drug Market Size by Country
  10. 12.3.1 Asia Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 Asia Therapeutic Monoclonal Antibodies Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 Asia Therapeutic Monoclonal Antibodies Drug Price by Country (2021-2032)
  13. 12.3.4 Japan
  14. 12.3.5 South Korea
  15. 12.3.6 India
  16. 12.3.7 Australia
  17. 12.3.8 Taiwan
  18. 12.3.9 Southeast Asia
13 South America, Middle East and Africa
  1. 13.1 SAMEA Therapeutic Monoclonal Antibodies Drug Market Size by Type
  2. 13.1.1 SAMEA Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2032)
  3. 13.1.2 SAMEA Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2032)
  4. 13.1.3 SAMEA Therapeutic Monoclonal Antibodies Drug Price by Type (2021-2032)
  5. 13.2 SAMEA Therapeutic Monoclonal Antibodies Drug Market Size by Application
  6. 13.2.1 SAMEA Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2032)
  7. 13.2.2 SAMEA Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2032)
  8. 13.2.3 SAMEA Therapeutic Monoclonal Antibodies Drug Price by Application (2021-2032)
  9. 13.3 SAMEA Therapeutic Monoclonal Antibodies Drug Market Size by Country
  10. 13.3.1 SAMEA Therapeutic Monoclonal Antibodies Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 13.3.2 SAMEA Therapeutic Monoclonal Antibodies Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 13.3.3 SAMEA Therapeutic Monoclonal Antibodies Drug Price by Country (2021-2032)
  13. 13.3.4 Brazil
  14. 13.3.5 Argentina
  15. 13.3.6 Chile
  16. 13.3.7 Colombia
  17. 13.3.8 Peru
  18. 13.3.9 Saudi Arabia
  19. 13.3.10 Israel
  20. 13.3.11 UAE
  21. 13.3.12 Turkey
  22. 13.3.13 Iran
  23. 13.3.14 Egypt
14 Value Chain and Sales Channels Analysis
  1. 14.1 Therapeutic Monoclonal Antibodies Drug Value Chain Analysis
  2. 14.1.1 Therapeutic Monoclonal Antibodies Drug Key Raw Materials
  3. 14.1.2 Raw Materials Key Suppliers
  4. 14.1.3 Manufacturing Cost Structure
  5. 14.1.4 Therapeutic Monoclonal Antibodies Drug Production Mode & Process
  6. 14.2 Therapeutic Monoclonal Antibodies Drug Sales Channels Analysis
  7. 14.2.1 Direct Comparison with Distribution Share
  8. 14.2.2 Therapeutic Monoclonal Antibodies Drug Distributors
  9. 14.2.3 Therapeutic Monoclonal Antibodies Drug Customers
15 Concluding Insights
    16 Appendix
    1. 16.1 Reasons for Doing This Study
    2. 16.2 Research Methodology
    3. 16.3 Research Process
    4. 16.4 Authors List of This Report
    5. 16.5 Data Source
    6. 16.5.1 Secondary Sources
    7. 16.5.2 Primary Sources
    8. 16.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst